Federal Register Notice: FDA is making available a revised draft guidance for industry entitled Draft Guidance on Risperidone. It provides specific recommendations on the design of bioequivalence studies to support ANDAs for risperidone injection. To download this guidance, click here. To view this notice, click here.
